clonazepam has been researched along with Parkinsonian Disorders in 4 studies
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "PGAD/RGS often coexists with restless legs syndrome (RLS)." | 1.42 | [A case of Parkinson's disease following restless genial sensation]. ( Nishinaka, K; Sawamura, M; Sekiya, T; Toma, K; Udaka, F; Unai, Y, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, VD | 1 |
| Gupta, HV | 1 |
| Espay, AJ | 1 |
| Hong, D | 1 |
| Cong, L | 1 |
| Zhong, S | 1 |
| He, Y | 1 |
| Xin, L | 1 |
| Gao, X | 1 |
| Zhang, J | 1 |
| Sawamura, M | 1 |
| Toma, K | 1 |
| Unai, Y | 1 |
| Sekiya, T | 1 |
| Nishinaka, K | 1 |
| Udaka, F | 1 |
| Schenck, CH | 1 |
| Mahowald, MW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Redictive Risk Factors of Conversion Into Idiopathic RBD. Italian Study [FAttori di Rischio PREdittivi di Conversione Nell'RBD Idiopatico. STudio ItalianO[NCT05262543] | 300 participants (Anticipated) | Observational | 2020-05-25 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for clonazepam and Parkinsonian Disorders
| Article | Year |
|---|---|
Clonazepam improves the symptoms of two siblings with novel variants in the SYNJ1 gene.
Topics: Adult; Amino Acid Sequence; Anticonvulsants; Clonazepam; Female; Follow-Up Studies; Genetic Variatio | 2019 |
REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Chronic Disease; Clonazepam; Diagnosis, Differential; Elec | 2002 |
2 other studies available for clonazepam and Parkinsonian Disorders
| Article | Year |
|---|---|
Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia.
Topics: Adrenergic beta-Antagonists; Aged; Aripiprazole; Clonazepam; Deprescriptions; Depressive Disorder; D | 2020 |
[A case of Parkinson's disease following restless genial sensation].
Topics: Benzothiazoles; Clonazepam; Drug Therapy, Combination; Female; Humans; Middle Aged; Parkinsonian Dis | 2015 |